🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, the spread of superbugs and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

According to findings released by a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors directly involved have expressed hope. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is deemed crucial to lessen the impact of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.